SAN DIEGO, March 02, 2025 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of BioAge Labs, Inc. (NASDAQ:BIOA) stock pursuant and/or traceable to BioAge Labs’ registration statement issued in connection with BioAge Labs’ initial public offering (“IPO”) held on September 26, 2024, have until Monday, March 10, 2025 to seek appointment as lead plaintiff of the BioAge Labs class action lawsuit. Captioned Soto v. BioAge Labs, Inc., No. 25-cv-00196 (N.D. Cal.), the BioAge Labs class action lawsuit charges BioAge Labs as well as certain of BioAge Labs’ top executives and directors with violations of the Securities Act of 1933.
If you suffered substantial losses and wish to serve as lead plaintiff of the BioAge Labs class action lawsuit, please provide your information here:
https://www.rgrdlaw.com/cases-bioage-labs-inc-class-action-lawsuit-bioa.html
You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com.
CASE ALLEGATIONS: BioAge Labs is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. In the IPO, BioAge Labs sold 12.65 million shares at $18.00 …
